FIELD NOTE
Britain just put AI device oversight into law. Washington put it on a guidance list.
On October 6 the UK government accepted all 44 recommendations of the National Commission into the Regulation of AI in Healthcare. Not 40 of 44, not 44 with caveats. The government response marks every recommendation “Accept” and sorts them into ten priority areas. The third one reads: shift towards stronger post-market assurance.
The commission was the MHRA’s own creation, stood up in September 2025 as an independent, non-statutory body chaired by Professor Alastair Denniston, with England’s Patient Safety Commissioner Henrietta Hughes as deputy. It published its report on September 10 after a year of evidence gathering the government says reached more than 12,000 people. Health innovation minister James Frith wrote that the UK “needs a new approach to AI product regulation in healthcare.” Then the government took the entire list.
Here is what is now on the record. The MHRA will use secondary legislation to update the definition of a medical device and introduce a new classification system for software and AI, following a consultation it intends to launch by spring 2027. Draft guidance on predetermined change control plans arrives in December. Recommendation 17 commits the agency to an enhanced post-market surveillance toolkit, “possibly including legislative reform.” Recommendation 19 commits it to a public database of adverse incident information. Staged authorization pathways get explored, with sandbox provisions riding in the forthcoming Regulating for Growth Bill. A cross-system program board reports quarterly, and an implementation roadmap with named responsibilities lands by spring 2027. AI Airlock, the agency’s regulatory sandbox, is open for applications on three more years of government funding, with the first wave of innovators selected in November and the whole phase pointed at post-market surveillance and lifecycle regulation.
Now set that against what Washington did five days earlier. On October 1, CDRH published its FY2027 guidance agenda. “Marketing Submission and Lifecycle Management Recommendations for Artificial Intelligence-Enabled Device Software Functions” sits second on a seven-item A-list of final guidances, finalizing a draft that has been out since January 2025. “Predetermined Change Control Plans for Medical Devices” is on the same list. The single A-list draft guidance is evidentiary recommendations for generative AI conversational devices for mental disorders. And FDA’s broader generative-AI discussion paper, published August 18, closes comments on October 19 under docket FDA-2026-N-7874 — a paper that asks questions about postmarket monitoring rather than answering them.
Both regulators have reached the same technical conclusion: a device that changes after clearance cannot be governed by a one-time review before it ships. They are filing that conclusion in very different places. The UK is heading toward statute, where the definition of a device and its classification actually change, and a surveillance duty can be written down and enforced. The FDA is heading toward final guidance, which represents the agency’s current thinking and binds no one, as every guidance document says on its own cover page.
The timing is awkward for a specific reason. In April, the MHRA was publicly working with the FDA to align device regulation and identify where future mutual recognition might fit, on top of three reliance routes the UK had already committed to for authorizations from the US, EU, Canada and Australia. Reliance works when both sides want the same evidence file. It is a harder argument when one side’s file carries an ongoing obligation that the other side’s does not. A US clearance can satisfy a UK premarket review. It cannot discharge a UK monitoring duty under UK law.
For anyone with an AI-enabled device and a UK commercial plan, the near calendar is shorter than the spring 2027 headline suggests. The change-management guidance is a December document, which means the drafting is happening now. The classification consultation will decide whether products currently outside device regulation get pulled in, and that is a secondary-legislation question, not a guidance question, which makes it slower to arrive and much harder to argue with once it does. And AI Airlock phase 3 is taking applications with selections in November, which is the cheapest seat available to a company that would rather help write a post-market surveillance regime than inherit one.
Trade coverage has framed the week as the UK backing continuous oversight. The sharper read is that the UK has decided lifecycle oversight is a legal obligation, and the United States has decided, for now, that it is a recommendation. Anyone building a regulatory plan on the assumption that those two converge is betting on a mutual-recognition conversation that just got materially harder.
SPONSORED BY RŌG HEALTH
A full commercial team for your next milestone.
No hiring required.
A raise, a launch, or a first hospital contract takes more than a good device. It takes messaging that holds up, investor and sales materials, a website, training, and regulatory and manufacturing partners who all understand where the company is headed. Most teams either try to hire for all of it before the milestone or piece it together from vendors who never talk to each other.
RŌG Health gives you that team now. We start with where you’re headed and what’s in the way. Then we bring our own people and a bench of partner firms in regulatory, manufacturing, and commercial execution, all working from the same plan and telling the same story. When the work is done, it adds up to one company instead of six deliverables.
If your next milestone needs more than your current team can carry, book 30 minutes with the RŌG Health team.
Want to put your brand in front of 28,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.